Recap: Neurocrine Biosciences Q3 Earnings

Shares of Neurocrine Biosciences NBIX decreased 13.34% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 7.78% year over year to $0.97, which beat the estimate of ($0.06).

Revenue of $258,500,000 rose by 16.39% year over year, which missed the estimate of $283,040,000.

Guidance

Neurocrine Biosciences hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 09, 2020

Time: 04:30 PM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1046/38078

Technicals

52-week high: $136.26

52-week low: $72.14

Price action over last quarter: down 25.52%

Company Overview

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.